Skip to main content
. 2017 Dec 26;9(8):7942–7948. doi: 10.18632/oncotarget.23678

Figure 3. Comparison of progression-free survival between younger and older groups with a cut-off age of 65.

Figure 3

Abbreviations: nivo, nivolumab; pem, pembrolizumab; HR, hazard ratio; CI, confidence interval.